Early changes in visuospatial episodic memory can help distinguish primary age‐related tauopathy from Alzheimer’s disease by Robinson, Andrew C. et al.
Neuropathol Appl Neurobiol. 2021;00:1–3.   | 1wileyonlinelibrary.com/journal/nan
Received: 8 February 2021  | Revised: 19 March 2021  | Accepted: 1 May 2021
DOI: 10.1111/nan.12726  
S C I E N T I F I C  C O R R E S P O N D E N C E
Early changes in visuospatial episodic memory can help 
distinguish primary age- related tauopathy from Alzheimer’s 
disease
The observation of neurofibrillary tangles (NFTs) without associated 
amyloid- beta (Aβ) in the brains of cognitively normal and cognitively 
impaired elderly individuals has, for many years, been a source of 
discussion and controversy. The term “primary age- related tauop-
athy” (PART) was introduced in 2014 and consensus guidelines for 
the condition were published.1 The clinical manifestations of PART 
have been described (see Ref.2 for review). A recent molecular im-
aging study suggested that mesial temporal tau load is associated 
with a decline in cognitive performance in those with no Aβ pathol-
ogy.3 Neuropsychiatric assessment has shown poor performance of 
executive function, processing speed, visuospatial ability, semantic 
memory and language in PART.2,4 Although the clinical trajectory in 
PART differs from that of Alzheimer's disease (AD), the very earliest 
cognitive changes in PART remain unclear.
Seventy- eight eligible participants from The University of 
Manchester Longitudinal Study of Cognition in Normal Healthy 
Old Age have been investigated for this study. They were assigned 
to one of four groups based on pathology at death: normal for age 
(n = 10), AD (n = 27), possible PART (n = 20) and definite PART 
(n = 21). During mid to late life, participants undertook four batches 
of cognitive tests assessing various aspects of cognition including 
memory, processing speed, fluid intelligence and crystallised intelli-
gence. Details regarding assignment of groupings, exclusion criteria, 
cognitive testing and pathological features have been published by 
us elsewhere.5- 7 The Memory Circle (MC) test (a test of visuospatial 
episodic memory) used here has previously been shown to identify 
individuals at risk of AD approximately 20 years before death.8
Demographic information, stratified by test point, can be found 
in Table S1. Braak stage, Thal phase and CERAD scores for each in-
dividual are shown in Table S2. Most subjects (70%) were female 
and cognitive impairment at death was present in 27% of partici-
pants. Mean age at death was 88.3 ± 5.9. Mean age at MC test 1 
was 65.0 ± 5.2, test 2 was 70.8 ± 5.1, test 3 was 75.3 ± 5.1 and test 
4 was 77.8 ± 5.5. There were significantly more females in the pos-
sible PART group compared to the definite PART group (p = 0.008). 
Cognitive impairment was more likely in AD group when compared 
to normal for age (p = 0.054), possible PART (χ2 = 6.031, p = 0.014) 
and definite PART (χ2 = 16.970, p < 0.001). Likewise, cognitive 
impairment was more likely in possible PART compared to definite 
PART (χ2 = 4.654, p = 0.048). Those considered possible PART died 
at a significantly older age than those with pathology normal for age 
(t(28) = −2.159, p = 0.040). There were no other significant differ-
ences in age at death or age at the various testing points between 
the groups. MC test 1 was conducted 23.4 ± 4.2 years before death, 
test 2 was 17.5 ± 4.0 years before death, test 3 was 13.4 ± 4.1 years 
before death and test 4 was 10.2 ± 3.9 years before death. Although 
there is no agreed timeline of prodromal stages of AD or PART, the 
number of years between initial MC tests (time points 1 and 2) and 
death places these testing periods well before the onset of overt 
manifestations of cognitive impairment or dementia in AD.
There were no significant differences between the groups in 
MC test scores at test point 1 (χ2(3) = 4.045, p = 0.257), but at test 
point 2 (χ2(3) = 8.874, p = 0.031) those with AD scored significantly 
lower than those with definite PART (U = 144, p = 0.006). Similarly, 
scores were significantly lower in those with possible PART com-
pared to definite PART (U = 128.5, p = 0.051). There were no sig-
nificant differences in test scores between the groups at test point 
3 (χ2(3) = 1.012, p = 0.798) or test point 4 (χ2(3) = 3.283, p = 0.350) 
(Figure 1). When considering the trajectories of test scores within 
each group, there were no significant differences between time 
points although there was a tendency for scores to decline over 
time in the AD group (χ2(3) = 6.641, p = 0.084). AD pathology, as 
measured by Braak stage, Thal phase and CERAD score, also cor-
related with MC test scores at time point 2. In addition, Thal phase 
correlated with MC test score at time point 1 and time point 4 (see 
Table S3).
On first sight, these results might appear counter intuitive. Loss 
of significance at the later time points may simply be due to fewer 
available test scores as participants die or drop out of the study. 
However, when considering prodromal- stage pathological changes 
and their effect on cognition, another possible explanation emerges. 
It is presumed that at time point 1 (23.4 ± 4.2 years before death), Aβ 
pathology is either absent or insufficient in all groups to affect cog-
nitive performance. By time point 2 (17.5 ± 4.0 years before death), 
Aβ pathology (and possibly tau pathology) will have increased in AD 
and possible PART to a level where subtle cognitive changes can 
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be detected. As no Aβ pathology will be present in definite PART 
their cognition will remain intact and scores will remain comparable 
to those with pathology normal for age. However, by time points 3 
(13.4 ± 4.1 years before death) and 4 (10.2 ± 3.9 years before death), 
tau may be present in all pathology groups, along with Aβ in the AD 
and possible PART groups. There may also be a degree of Aβ pa-
thology present in those normal for age. Thus, the combination of 
these early pathologies may lead to a convergence in MC test scores 
again. If later time points had been available, a more severe decline 
in MC scores in AD compared to possible/definite PART would have 
been anticipated as the rate of both Aβ and tau pathology acceler-
ates compared to PART.
In this short correspondence, we are raising the possibility that 
PART can be differentiated from AD very early on in the disease 
course using a simple cognitive test. To further elucidate these find-
ings, replication in a larger cohort will be needed and questions re-
garding co- morbidities will need to be more extensively considered. 
With these points in mind, we tentatively conclude that Aβ depo-
sition has a subtle effect on visuospatial episodic memory in early 
AD and possible PART. This finding enables a “window of opportu-
nity” to distinguish those who will develop AD from those who will 
develop definite PART. This early detectable difference in cognition 
however is transient, being overcome by onset and progression of 
Aβ and tau pathology in AD and possible PART, and tau pathology 
in definite PART. Present findings indicate that PART is a separate 
entity to AD.
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F I G U R E  1  Boxplots comparing MC 
scores between pathology groups at 
the four testing time points. The boxes 
represent the interquartile (IQ) range 
which contains the middle 50% of the 
records. The whiskers represent the 
highest and lowest values which are 
no greater than 1.5 times the IQ range. 
The line across the boxes indicates the 
median. Differences between pathology 
groups for MC scores were analysed with 
the Mann- Whitney U test
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